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Objective: Epidural injection of hyaluronic acid may prevent adhesion formation after spine surgery, but the compounds 
used to stabilize hyaluronidase could interfere with its anti-adhesion effects. The present study was conducted as a clinical 
trial to evaluate the efficacy and safety of an experimental medical gel in preventing adhesion formation.
Methods: This study was designed as a multicenter, randomized, double-blind, and comparative controlled clinical trial with 
an observation period of 6 weeks. Subjects were randomly assigned into two groups: group A with sodium hyaluronate + 
1,4-butanediol diglycidyl ether (BDDE) and group B with sodium hyaluronate + sodium carboxymethylcellulose (CMC). Visual 
analogue scale (VAS) of back and leg pain and the Oswestry disability index (ODI) and scar score ratings were assessed 
after surgery.
Results: Mean scar grade was 2.37±1.13 in group A and 2.75±0.97 in group B, a statistically significant difference (p=0.012). 
VAS of back and leg pain and ODI scores decreased significantly from baseline to 3 and 6 weeks postoperatively in both 
groups (p<0.001). However, VAS and ODI scores were not statistically different between groups A and B at baseline or at 
3 and 6 weeks after operation (p>0.3). The number of adverse reactions related to the anti-adhesion gels was not statistically 
different (p=0.569), but subsequent analysis of nervous adverse reactions showed group B was superior with a statistically 
difference (p=0.027).
Conclusion: Sodium hyaluronate with BDDE demonstrated similar anti-adhesion properties to sodium hyaluronate with CMC. 
But, care should be used to nervous adverse reactions by using sodium hyaluronate with BDDE.
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INTRODUCTION
Failed back surgery syndrome (FBSS) is defined as the pre- 
sence of persistent or severe disabling pain that continues after 
spinal surgery2,23,25). According to previous studies, surgical 
treatment of intervertebral disc herniation showed relatively 
good results in 90% of patients, but failed in 10%17,26). Epidural 
fibrosis, which can be occurred in the course of surgical treat- 
ment, may be the cause of such poor results5), and in previous 
studies, was observed in 24% of recently failed lumbar spine 
surgeries19,32). Moreover, the degree of back pain or nerve 
root pain could be reflective of the extent of spinal epidural 
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Table 1. Peridural scar score
Scar score Description
0 No/trace scar
1 0-25% of quadrant filled with scar
2 25-50% of quadrant filled with scar
3 50-75% of quadrant filled with scar
4  >75% of quadrant filled with scar
Fig. 1. The positions of five standard cross-sectional magnetic
resonance images.
fibrosis21,27). Recently, various surgical materials prepared via 
polymer synthesis from natural resources to prevent or reduce 
adhesions after surgery have been developed12,18,28,31,32). One 
such substance, hyaluronidase, has been administered to reduce 
swelling and edema in tissues by dissolving the glucosaminic 
bonds between hyaluronic acid and connective tissue. Utilizing 
this process, epidural injection of hyaluronic acid may prevent 
adhesion formation. However, the compounds used to stabilize 
hyaluronidase could interfere with its anti-adhesion effects. 
Previously, unpublished data from an effect test report of 
sodium hyaluronate + 1,4-butanediol diglycidyl ether (BDDE) 
demonstrated a greater anti-adhesion effect for BDDE than 
for other compounds of sodium hyaluronate. Here the authors 
conducted a clinical trial of an experimental medical gel com- 
posed of hyaluronate + BDDE to evaluate its effectiveness and 
safety in preventing adhesion formation.
MATERIALS AND METHODS
This clinical trial was designed as a multicenter, randomized, 
double-blind, and comparative controlled clinical trial. All sub- 
jects were volunteers and provided signed informed consent. 
In total, 74 cases that satisfied the selection criteria were en- 
rolled for the study period of 24 months, and 68 cases were 
included in the final analyses, as 6 cases dropped out during 
the observation period (6 weeks for each case). The subjects 
were randomly divided into one of two groups according to 
type of anti-adhesion agent to be applied: group A received 
the anti-adhesion gel HyFence LV® (sodium hyaluronate + 
1,4-Butanediol diglycidyl ether (BDDE), Cha Bio & Diostech, 
Seoul, Republic of Korea) and group B was treated with 
Guardix-SOL® (sodium hyaluronate + sodium carboxymethyl- 
cellulose, Genewel Co, Seongnam, Republic of Korea). All 
subjects received a randomly assigned anti-adhesion gel before 
wound closure after standard discectomy. Clinical outcomes 
were evaluated according to visual analogue scale (VAS) assess- 
ment and the Korean version of the Oswestry Disability Index 
(ODI) before surgery as well as 3 and 6 weeks after the investi- 
gational medical agents had been applied. Radiological out- 
comes were evaluated by magnetic resonance imaging (MRI), 
which was performed at 6 weeks after surgery, and graded 
according to scar formation by three different independent 
evaluators blinded to information about the subjects. Scar score 
ratings were graded according to the degree of dural scar score 
in the spinal canal as presented in Fig. 1 and Table 1. For 
each subject, five cross-sectional MR images were checked, 
and each cross-sectional image was divided into four quad- 
rants, so that a total of 20 quadrant cross-sectional MR images 
per subject were evaluated27). The checked scar grades of 3 
different observers were all categorized by the scar grades and 
the mean scar grade was calculated.
The inclusion criteria for this study consisted of (1) patients 
older than 20 years and younger than 65 years of age; (2) diag- 
nosis of lumbar disc herniation at spinal level L4-L5 or L5-S1 
with radiculopathic symptoms refractory to conservative treat- 
ment for a minimum of 2 weeks; (3) scheduled for first surgery 
to remove single level and unilateral lumbar disc herniation; 
(4) could understand and follow instructions; and (5) could 
provide written consent to participate in the clinical trial. The 
exclusion criteria consisted of (1) patients with multi-level, far 
lateral or bilateral lumbar disc herniation; (2) those with dege- 
nerative spinal cord disease or scoliosis; (3) exhibited hyaluronic 
acid-sensitive side effects; (4) involved lymphatic or blood clo- 
tting disorders or were administered a blood coagulant; (5) had 
uncontrolled diabetes; (6) received oral steroid medication 
within 4 weeks, epidural steroid injection within 10 days or 
were administered aspirin and/or non-steroidal anti-inflamma- 
tory agents within 7 days from the baseline study period; (7) 
had collagen-vascular disease, self-immune diseases such as rheu- 
matoid arthritis or systemic lupus erythematosus, or malignant 
tumors within 5 years; (8) demonstrated spinal cord angio- 
graphy or lumbar puncture within 24 hours from the baseline 
study period; (9) showed reduced immunity or abnormal labo- 
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Table 2. Scar scores between the two groups
Group A Group B p-value
Device HyFence LV Guardix-SOL
Composition HA+CMC HA+BDDE
N 34 34
Grade 0  3  0 0.048
Grade 1 21  9
Grade 2 35 37
Grade 3 21 27
Grade 4 22 29
Mean Grade 2.37±1.13 2.75±0.97 0.012
HA, sodium hyaluronate; CMC, sodium carboxymethylcellulose; 
BDDE, 1,4-Butanediol diglycidyl ether
ratory tests (hematologic, blood chemical, and urine test) du- 
ring screening tests; (10) have had or currently had serious 
disability affecting the cardiovascular, digestive, respiratory, 
endocrine, or central nervous system, or clinical mental illness; 
(11) participated in other clinical trials within 30 days; or (12) 
were pregnant, lactating, or on contraceptive medication.
Student’s t-test and ANOVA test were conducted to estimate 
the reliability of radiological and clinical outcomes for each 
group. Kruskal-Wallis test was used to compare outcomes 
before application and at follow-up. The mean scar grade of 
each group was considered as interval scales for easier com- 
parison between the groups, although this should be consi- 
dered as ordinal scales. All statistical analyses were performed 
using SPSS software version 12 (SPSS Inc., Chicago, IL, USA), 
and statistical significance was defined as p<0.05.
RESULTS
The results concerning scar formation are presented in Table 
1. No statistical difference was observed in the demographic 
data between groups A and B. Scar scores differed according 
to the different anti-adhesion gels applied, and comprised 3 
cases of grade 0, 21 cases of grade 1, 35 cases of grade 2, 21 
cases of grade 3, and 22 cases of grade 4 scarring in group 
A. Group B comprised no cases of grade 0, 9 cases of grade 1, 
37 cases of grade 2, 27 cases of grade 3, and 29 cases of grade 
4 scarring. Statistical analysis using the chisquare test gene- 
rated a result of 0.048. The mean scar grade for each group 
was 2.37±1.13 in group A and 2.75±0.97 in group B, which 
was a statistically significant difference (p=0.012) (Table 2).
In group A, mean back pain VAS decreased significantly 
(p<0.001) from a baseline of 51.94±48.72 to a 3-week post- 
operative score of 20.28±20.57 and a 6-week postoperative 
score of 21.35±22.77. Similarly, in group B, preoperative 
mean back pain VAS score decreased significantly (p<0.001) 
from 48.72±27.87 to 25.24±24.45 at 3 weeks postoperative 
and 20.41±21.97 at 6 weeks postoperative. Mean leg pain 
VAS significantly decreased (p<0.001) from a baseline of 
63.47±22.79 to a 3-weeks postoperative score of 23.22± 
23.75 and 6-week postoperative score of 20.59±26.05 in 
group A, and similarly, from a preoperative score of 66.59± 
20.11 to a 3-week postoperative score of 28.76±27.30 and 
a 6-week postoperative score of 23.32±26.92 in group B
(p<0.001). Similar to the VAS results, in group A, mean ODI 
score decreased significantly (p<0.001) from a baseline score 
of 42.11±16.89% to 27.93±14.92% at 3 weeks postoperative 
and 22.64±14.87% at 6 weeks postoperative. In group B, 
mean preoperative ODI score decreased from 44.72±19.11% 
to 31.26±15.41% at 3 weeks postoperative and 26.62±16.98 
% at 6 weeks postoperative (Fig. 2). Altogether, back pain 
VAS, leg pain VAS and ODI scores were not statistically diffe- 
rent between the two groups at baseline or at 3 and 6 weeks 
after operation (p>0.3).
Observed adverse reactions are summarized in Table 3. 
Adverse reactions were categorized as musculoskeletal and 
connective tissue disorders; injury, poisoning and procedural 
complications; gastrointestinal disorders; nervous system dis- 
orders; general disorders and administration site conditions; 
renal and urinary disorders; infections and infestations; investi- 
gations; psychiatric disorders; skin and subcutaneous tissue 
disorders; respiratory, thoracic and mediastinal disorders; 
metabolism and nutrition disorders; hepatobiliary disorders; 
or vascular disorders. Relevant disease or symptoms for each 
category are listed in Table 3. In group A, 113 events of an 
adverse reaction among 33 cases (91.7%) were recorded, while 
98 events among 24 cases (68.6%) were observed in group B. 
Although the number of cases of an adverse reaction between 
the two groups was statistically different (p=0.018), the num- 
ber of adverse reactions was not statistically different (p= 
0.569). Most of the adverse reactions were minor (two major 
adverse reactions in group B included one case of wound 
infection and a case of intervertebral disc protrusion), and all 
adverse reactions were unrelated to the device. In regards to 
adverse reaction category, nervous system disorders were more 
frequently recorded for group A than group B; 14 events were 
recorded among 12 patients in group A, while 7 events among 
4 patients were noted in group B (p=0.027). But nervous 
adverse reactions broadly included symptoms of paraesthesia, 
dizziness, hypoesthesia, carpal tunnel syndrome, cerebral arte- 
riosclerosis, cervicobrachial syndrome, headache and radicular 
pain. Concerning the presenting symptoms of the adverse ner- 
vous system disorders, five events of paraesthesia in group A 
and one event in group B were observed; one event of dizziness 
in group A and 4 events in group B were recorded; 4 events 
Ji GY et al.
44  www.e-kjs.org
Fig. 2. Clinical results between the two groups: visual analog 
scale for back and leg pain, and Oswestry disability index.
Fig. 3. Postoperative MR. (A) Scantly observed scar tissue; and
(B) Compressive scar tissue in post-laminectomy site.
of hypoesthesia in group A and one event in group B were 
noted; one event each of carpal tunnel syndrome, cerebral 
arteriosclerosis, cervicobrachial syndrome and radicular pain 
were recorded in group A; and finally, a single event of head- 
ache was reported in group B. Subsequent analysis of nervous 
adverse reactions that could related to the anti-adhesion gels 
(e.g. paraesthesia, hypoesthesia and radicular pain) showed a 
statistically difference (p=0.013). In other adverse reaction cate- 
gories, no statistical difference was observed.
DISCUSSION
Postoperative fibrosis is a natural course of wound healing12,24). 
Fibroblasts, originating from the overlying muscles and follo- 
wing extension of postoperative hematoma into the vertebral 
canal, release excessive extracellular matrix and cause the 
abundance and strong adhesion of the tissue16,29). Thus, the 
migration of fibroblasts from the raw surface of the erector 
spine musculature was stated as the source of postoperative 
scar tissue10,16). But, epidural adhesion was considered as a 
major contributing factor to postsurgery radicular pain and 
lower extremity weakness after laminectomy3,7,11,18,19,22,24,27). 
Moreover, epidural adhesion is thought to be with the increased 
complication rates associated with spinal reinterventions4,6,9,13). 
A general feature seems to be the requirement for direct con- 
tact between exposed dura and invading fibroblasts, thereby 
allowing for the generation of localized dense fibrotic tissue 
and tethering of the thecal sac and nerve roots24). Numerous 
experimental and clinical studies had focused to prevent 
epidural adhesion formation using prophylactic intervention. 
Such treatments have included modified surgical approaches, 
antiinflammatory agents, antibiotics, and a wide variety of bio- 
logical and synthetic barriers, including fat grafts, hyaluronan, 
collagen, gelatin foam, polylactide films, ADCON-L and more 
recently, Oxiplex1/SP Gel.1,6,8,11,13-15,20,21,24,27,33). In general 
concept, the ideal agent for preventing peridural adhesion and 
fibrosis should include the following properties: (1) preven- 
tion of scar tissue adhesion to the dural tissues, (2) prevention 
of the development of leptomeningeal arachnoiditis, (3) no 
potential to impair dural healing following tearing and CSF 
leakage and (4) no capability to induce excessive inflammation 
around neural tissues24).
In the present study, scar scores were significantly different 
between the two medical agents. The mean scar grade for group 
A was 2.46±0.71 and 2.70±0.71 for group B, a statistically 
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Table 3. Adverse effects observed between the two groups
Group A (n=36) Group B (n=35) p-value
Cases of adverse reactions n=33 (91.7%) n=24 (68.6%) 0.018
Events of adverse reactions 113 98 0.569
Major adverse reactions   0  2
Minor adverse reactions 113 96 0.146
Device related adverse reactions   0  0
Non-device related adverse reactions 113 98 N/A
Adverse Reactions
Musculoskeletal and connective tissue disorders1 23 (n=12, 33.3%) 18 (n=9, 25.7%) 0.482
Injury, poisoning and procedural complications2 21 (n=16, 44.4%) 18 (n=12, 34.3%) 0.381
Gastrointestinal disorders3 20 (n=16, 44.4%) 18 (n=12, 34.3%) 0.381
Nervous system disorders4 14 (n=12, 33.3%)  7 (n=4, 11.4%) 0.027
General disorders and administration site conditions5  8 (n=8, 22.2%)  9 (n=8, 22.9%) 0.949
Renal and urinary disorders6  7 (n=7, 19.4%)  7 (n=7, 20.0%) 0.953
Infections and infestations7  5 (n=3, 8.3%)  6 (n=6, 17.1%) 0.265
Investigations8  5 (n=4, 11.1%)  4 (n=4, 11.4%) 0.966
Psychiatric disorders9  4 (n=4, 11.1%)  2 (n=2, 5.7%) 0.413
Skin and subcutaneous tissue disorders10  3 (n=2, 5.6%)  3 (n=3, 8.6%) 0.620
Respiratory, thoracic and mediastinal disorders11  2 (n=2, 5.6%)  2 (n=1, 2.9%) 0.572
Metabolism and nutrition disorders12  0 (n=0, 0.0%)  2 (n=2, 5.7%) 0.146
Hepatobiliary disorders13  0 (n=0, 0.0%)  2 (n=1, 2.9%) 0.307
Vascular disorders14  1 (n=1, 2.8%)  0 (n=0, 0.0%) 0.321
1Back pain, pain in an extremity, musculoskeletal pain, intervertebral disc protrusion, muscular weakness, arthralgia, musculoskeletal 
stiffness, myalgia, and myofascial pain syndrome; 2Procedural pain, post procedural complication, procedural hypertension, wound 
secretion, contusion, open wound, post procedural constipation, post procedural discharge, post procedural discomfort, post procedural
edema, post procedural swelling, procedural nausea, and toxicity to various agents; 3Constipation, nausea, dyspepsia, vomiting, aphthous 
stomatitis, diarrhea, gastrointestinal disorder, abdominal distension, abdominal pain, dry mouth, hematochezia, and reflux esophagitis; 
4Paraesthesia, dizziness, hypoesthesia, carpal tunnel syndrome, cerebral arteriosclerosis, cervicobrachial syndrome, headache, and radi- 
cular pain; 5Pyrexia, chills, hernia, pain, and tenderness; 6Dysuria and urinary retention; 7Nasopharyngitis, gastroenteritis, upper respiratory 
tract infection, and wound infection; 8Increased blood pressure, increased alanine aminotransferase, and increased aspartate aminot- 
ransferase; 9Insomnia, anxiety, and depression; 10Urticaria, dermatitis contact, pruritus, and rash; 11Atelectasis, cough, dyspnea, and 
oropharyngeal pain; 12Decreased appetite and hypoalbuminemia; 13Hepatic cyst and hepatic steatosis; 14Hypertension
significant difference (p=0.05). Moreover, all back pain VAS, 
leg pain VAS and ODI scores decreased significantly (p< 
0.001) from baseline to 3 and 6 weeks postoperative. These 
results indicated that 1,4-butanediol diglycidyl ether is a more 
effective compound than carboxymethyl cellulose in stabili- 
zing sodium hyaluronate, and substantiated our results from 
a previous, unpublished preliminary study in rats. Although 
no absolute proof has been presented and the invasion was 
needed, the authors discerned that 1,4-butanediol diglycidyl 
ether is a more effective stabilizer of sodium hyaluronate after 
spine operation as a result of its molecular structure and other 
unknown variables. However, interestingly, although all of the 
adverse reactions observed in this study were not related to 
the agent, nervous system disorders were more frequently 
reported in 1,4-butanediol diglycidyl ether administered sub- 
jects with statistical significance (p=0.027). Indeed, the pre- 
senting symptoms were directly correlated with nerve root 
irritation such as paraesthesia or hypoesthesia. Therefore, care- 
ful patient selection in the use of sodium hyaluronate with 
1,4-butanediol diglycidyl ether is needed and more specific 
study concerning this issue is warranted.
There were some limitations of this study that warrant con- 
sideration. First, this study was initially designed as a nonin- 
feriority test of sodium hyaluronate with 1,4-butanediol digly- 
cidyl ether compared the other anti-adhesive products; there- 
fore, further compatible randomized control study is needed. 
Second, scar formation was checked not by clinical study, but 
by imaging studies. Therefore, the actual scar formation is not 
clear. Indeed, the postoperative peridural scar was commonly 
studied after postoperative 6 months, but this study was evalua- 
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ted at 6 weeks after operation. So, the MR finding is susbjective 
postoperative epidural scar, but, it could be misjudge of the 
epidural soft tissue edema or hemorrhage. So, further elonga- 
ted study is needed to confirm the scar formation by the adhe- 
sion formation materials. Despite these limitations, the present 
study was designed as a multicenter, randomized, single-blind, 
and comparative controlled clinical trial. The results indicated 
that stabilizing materials of sodium hyaluronate interfere with 
the anti-adhesive function thereof after spine surgery and that 
1,4-butanediol diglycidyl ether is a more effective compound 
than carboxymethylcellulose in stabilizing sodium hyaluronate.
CONCLUSION
Sodium hyaluronate with 1,4-butanediol diglycidyl ether 
demonstrated better anti-adhesion properties than sodium hya- 
luronate with carboxymethylcellulose in patients after lumbar 
discectomy. However, further research could help to know its 
ambiguous effect on the neural tissues.
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